Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06640361 | A Study of Olverembatinib in SDH-deficient GIST. | PHASE3 | RECRUITING | 40 | — | — | Nov 11, 2024 | Jun 30, 2029 | Dec 27, 2024 | 1 | China |
Proportion of subjects who do not experience disease progression or death after the first dose of treatment as assessed by Independent Review Committee.
| Arm | Type | Description |
|---|---|---|
| Olverembatinib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Olverembatinib | DRUG | Oral administration with meal, QOD, every 28 days for a cycle. |
Inclusion Criteria: 1. Histologically and/or cytologically confirmed GIST, immunohistochemistry with loss of SDHB expression, and failure of at least one prior systemic therapy. Defined as disease progression or intolerable as judged by the investigator. 2. Must have at least one measurable target ...